Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1975 Feb 8;1(5953):299–303. doi: 10.1136/bmj.1.5953.299

Bromocriptine treatment of acromegaly.

M O Thorner, A Chait, M Aitken, G Benker, S R Bloom, C H Mortimer, P Sanders, A S Mason, G M Besser
PMCID: PMC1672473  PMID: 1111790

Abstract

The effects of oral bromocriptine in acromegaly have been studied. A dose of 5 mg six-hourly suppressed circulating growth hormone (GH) levels in nine out of 11 patients treated for seven to 11 weeks. This was associated with considerable clinical improvement in all patients, with abolition of excessive sweating, reduction in soft-tissue thichening, loosening of rings, decrease in shoe size, improvement in facial features, and loosening of dentures. Metabolic changes included improvement in glucose tolerance and reduction in hydroxyproline excretion. Unlike the actions of growth hormone release inhibiting hormone the suppression of GH was not accompanied by a reduction in insulin or glucagon secretion, though prolactin levels were suppressed. Side effects other than mild constipation were not seen when the full dose regimen was reached by slowly increasing the dose from 2-5 mg once daily. Bromocriptine holds promise as a safe and orally effective medical treatment to augment surgical or radiotherapeutic measures directed at the pituitary tumour. Its efficacy during longterm administration remains to be established.

Full text

PDF
299

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackard W. G., Hubbell G. J. Stimulatory effect of exogenous catecholamines on plasma HGH concentrations in presence of beta adrenergic blockade. Metabolism. 1970 Jul;19(7):547–552. doi: 10.1016/0026-0495(70)90010-7. [DOI] [PubMed] [Google Scholar]
  2. Bloom S. R., Mortimer C. H., Thorner M. O., Besser G. M., Hall R., Gomez-Pan A., Roy V. M., Russell R. C., Coy D. H., Kastin A. J. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974 Nov 9;2(7889):1106–1109. doi: 10.1016/s0140-6736(74)90869-1. [DOI] [PubMed] [Google Scholar]
  3. Del Pozo E., Friesen H., Burmeister P. Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report. Schweiz Med Wochenschr. 1973 Jun 9;103(23):847–848. [PubMed] [Google Scholar]
  4. Eddy R. L., Jones A. L., Chakmakjian Z. H., Silverthorne M. C. Effect of levodopa (L-DOPA) on human hypophyseal tropic hormone release. J Clin Endocrinol Metab. 1971 Oct;33(4):709–712. doi: 10.1210/jcem-33-4-709. [DOI] [PubMed] [Google Scholar]
  5. Flückiger E., Wagner H. R. 2-Br-alpha-Ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte. Experientia. 1968 Nov 15;24(11):1130–1131. doi: 10.1007/BF02147804. [DOI] [PubMed] [Google Scholar]
  6. Forsyth I. A., Besser G. M., Edwards C. R., Francis L., Myres R. P. Plasma prolactin activity in inappropriate lactation. Br Med J. 1971 Jul 24;3(5768):225–227. doi: 10.1136/bmj.3.5768.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frohman L. A. Clinical neuropharmacology of hypothalamic releasing factors. N Engl J Med. 1972 Jun 29;286(26):1391–1397. doi: 10.1056/NEJM197206292862606. [DOI] [PubMed] [Google Scholar]
  8. Hall R., Besser G. M., Schally A. V., Coy D. H., Evered D., Goldie D. J., Kastin A. J., McNeilly A. S., Mortimer C. H., Phenekos C. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet. 1973 Sep 15;2(7829):581–584. doi: 10.1016/s0140-6736(73)92413-6. [DOI] [PubMed] [Google Scholar]
  9. Hanssen K. F. Immunoreactive growth hormone in human urine. Acta Endocrinol (Copenh) 1972 Dec;71(4):665–676. doi: 10.1530/acta.0.0710665. [DOI] [PubMed] [Google Scholar]
  10. Kansal P. C., Buse J., Talbert O. R., Buse M. G. The effect of L-dopa on plasma growth hormone, insulin, and thyroxine. J Clin Endocrinol Metab. 1972 Jan;34(1):99–105. doi: 10.1210/jcem-34-1-99. [DOI] [PubMed] [Google Scholar]
  11. Leutenegger M., Audibert A., Caron J., Renard A. Les galactorrhées de la femme. Schweiz Rundsch Med Prax. 1972 Jun 6;61(23):762–766. [PubMed] [Google Scholar]
  12. Liuzzi A., Chiodini P. G., Botalla L., Cremascoli G., Silvestrini F. Inhibitory effect of L-Dopa on GH release in acromegalic patients. J Clin Endocrinol Metab. 1972 Dec;35(6):941–943. doi: 10.1210/jcem-35-6-941. [DOI] [PubMed] [Google Scholar]
  13. McNeilly A. S. Radioimmunoassay of human prolactin. Proc R Soc Med. 1973 Sep;66(9):863–864. [PMC free article] [PubMed] [Google Scholar]
  14. Mims R. B., Stein R. B., Bethune J. E. The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects. J Clin Endocrinol Metab. 1973 Jul;37(1):34–39. doi: 10.1210/jcem-37-1-34. [DOI] [PubMed] [Google Scholar]
  15. Mortimer C. H., Tunbridge W. M., Carr D., Yeomans L., Lind T., Coy D. H., Bloom S. R., Kastin A., Mallinson C. N., Besser G. M. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet. 1974 Apr 20;1(7860):697–701. doi: 10.1016/s0140-6736(74)92903-1. [DOI] [PubMed] [Google Scholar]
  16. Rees L., Butler P. W., Gosling C., Besser G. M. Adrenergic blockade and the corticosteroid and growth hormone responses to methylamphetamine. Nature. 1970 Nov 7;228(5271):565–566. doi: 10.1038/228565a0. [DOI] [PubMed] [Google Scholar]
  17. Stegemann H., Stalder K. Determination of hydroxyproline. Clin Chim Acta. 1967 Nov;18(2):267–273. doi: 10.1016/0009-8981(67)90167-2. [DOI] [PubMed] [Google Scholar]
  18. Sönksen P. H., Tompkins C. V., Srivastava M. C., Nabarro J. D. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med. 1973 Nov;45(5):633–654. doi: 10.1042/cs0450633. [DOI] [PubMed] [Google Scholar]
  19. Thorner M. O., McNeilly A. S., Hagan C., Besser G. M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J. 1974 May 25;2(5916):419–422. doi: 10.1136/bmj.2.5916.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Varga L., Wenner R., Del Pozo E. Treatment of galactorrhea-amenorrhea syndrome with Br-ergocryptine (CB 154): restoration of ovulatory function and fertility. Am J Obstet Gynecol. 1973 Sep 1;117(1):75–79. doi: 10.1016/0002-9378(73)90731-x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES